Pfizer has announced the appointment of Chris Boshoff as Chief Scientific Officer and President of Research & Development, effective January 1, 2025. Boshoff, who previously served as Chief Oncology Officer and Executive Vice President, will succeed Dr. Mikael Dolsten. In his new role, Boshoff will oversee all research and development functions across all therapeutic areas and will continue to report to Pfizer’s Chairman and CEO, Albert Bourla. With more than 11 years at Pfizer, Boshoff has an impressive track record, having delivered 24 innovative medicines and biosimilars across more than 30 indications. His extensive experience includes leadership roles in oncology and rare disease development, as well as founding Director of the University College London (UCL) Cancer Institute.
Pfizer’s Oncology R&D organization will maintain its structure under Boshoff, with Roger Dansey serving as Interim Chief Oncology Officer. Johanna Bendell will join Pfizer from Roche in 2025 as Chief Development Officer, Oncology, ensuring a smooth transition. Boshoff’s vision for Pfizer’s R&D aims to drive impactful breakthrough medicines with blockbuster potential. Pfizer, a global leader in biopharmaceuticals, is dedicated to advancing wellness and improving lives through innovative medicines and vaccines.
